Abstract
One of the most common causes of hospital admission and death in patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is acute respiratory distress syndrome (ARDS), a clinical syndrome characterised by acute lung inflammation and increased-permeability pulmonary oedema due to injury to the alveolar capillary barrier. As clinicians care for a surge of patients with ARDS due to COVID-19, two questions arise. First, is COVID-19-associated ARDS intrinsically different from ARDS unrelated to COVID-19? The answer to this question has implications for the use of evidence-based therapies such as lung-protective mechanical ventilation, proning, and conservative fluid management in COVID-19-associated ARDS.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
